Literature DB >> 8493018

Excimer laser photorefractive keratectomy for myopia. Clinical results in sighted eyes.

B Tengroth1, D Epstein, P Fagerholm, H Hamberg-Nyström, T D Fitzsimmons.   

Abstract

PURPOSE: To evaluate the refractive results of excimer laser photorefractive keratectomy (PRK) performed on normal, sighted myopic eyes; to assess the role of postoperative topical steroid treatment in patients with PRK; and to study the regression of effect.
METHODS: An argon fluoride 193-nm excimer laser was used. Photorefractive keratectomy was performed on 420 eyes with preoperative refraction ranging from -1.25 to -7.50 diopters (D). Minimum follow-up time was 12 months, and 194 of the eyes were followed for 15 months. Postoperative treatment generally consisted of topical dexamethasone for 3 months, but in a sub-study, some eyes were treated for only 5 weeks.
RESULTS: Mean refraction (spherical equivalent +/- standard deviation) at 12 months was -0.04 +/- 0.84 D and at 15 months -0.22 +/- 0.78 D. At 12 months postoperatively, 86% of the eyes were within 1.00 D of emmetropia, at 15 months 87%. At 12 months, 91% of the eyes had an uncorrected visual acuity of at least 20/40, at 15 months 87%. Eyes treated with dexamethasone for 3 months regressed significantly less than those treated for only 5 weeks (P < 0.01). Dexamethasone also was effective in reversing regression later in the postoperative course. Eyes with preoperative myopia up to 4.90 D had significantly better refractive results at 12 months than eyes with myopia ranging from 5.00 to 7.50 D (P < 0.01).
CONCLUSION: These data show that excimer laser PRK can correct myopia with good predictability. Results at 12 and 15 months tend to suggest stability of postoperative refraction. Regression of effect was more common in higher myopes. Topical steroids postoperatively seem to play a crucial role for the refractive result.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8493018     DOI: 10.1016/s0161-6420(93)31581-2

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  14 in total

1.  Expression of cellular fibronectin and tenascin in the rabbit cornea after excimer laser photorefractive keratectomy: a 12 month study.

Authors:  T Latvala; K Tervo; R Mustonen; T Tervo
Journal:  Br J Ophthalmol       Date:  1995-01       Impact factor: 4.638

2.  Excimer retreatment for scarring and regression after photorefractive keratectomy for myopia.

Authors:  G Sutton; R S Kalski; M A Lawless; C Rogers
Journal:  Br J Ophthalmol       Date:  1995-08       Impact factor: 4.638

3.  Effect of ablation profile on wound healing and visual performance 1 year after excimer laser photorefractive keratectomy.

Authors:  M C Corbett; S Verma; D P O'Brart; K M Oliver; G Heacock; J Marshall
Journal:  Br J Ophthalmol       Date:  1996-03       Impact factor: 4.638

4.  Photorefractive keratectomy.

Authors:  P J McDonnell
Journal:  West J Med       Date:  1997-02

5.  Confocal microscopy reveals persisting stromal changes after myopic photorefractive keratectomy in zero haze corneas.

Authors:  M Böhnke; A Thaer; I Schipper
Journal:  Br J Ophthalmol       Date:  1998-12       Impact factor: 4.638

Review 6.  Treating myopia with the excimer laser: the present position.

Authors:  D S Gartry
Journal:  BMJ       Date:  1995-04-15

7.  Stray light in photorefractive keratectomy for myopia.

Authors:  H G Veraart; T J van den Berg; R Hennekes; A M Adank
Journal:  Doc Ophthalmol       Date:  1995       Impact factor: 2.379

8.  Keratorefractive surgery.

Authors:  M R Mandel
Journal:  West J Med       Date:  1994-12

9.  Excimer laser treatment for high and extreme myopia.

Authors:  H R Taylor; C A Carson
Journal:  Trans Am Ophthalmol Soc       Date:  1994

10.  Increased release of tenascin in tear fluid after photorefractive keratectomy.

Authors:  M Vesaluoma; S Ylätupa; P Mertaniemi; K Tervo; P Partanen; T Tervo
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1995-08       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.